Palb2-, Brca1- or Brca2- deficient tumor cells in comparison to KPC or Palb2flox/+-KPC tumor cells are exquisitely sensitive to DNA damage inducing agents, including Olaparib, MMC and Cisplatin. This evidence concerns the gene BRCA1 and neoplasm.